Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma

Phase 1

Completed

• Conditions: Melanoma (Skin)

• Registration Number: NCT00039325
• Lead Sponsor: Jonsson Comprehensive Cancer Center

Brief Summary

RATIONALE: Vaccines made by inserting a laboratory-treated gene into a person's white blood cells may make the body build an immune response to kill tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy and to see how well it works in treating patients with stage IV or recurrent malignant melanoma.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-03
• Study First Submitted: 2002-06-06
• Study First Submitted QC: 2003-01-26
• Study First Posted: 2003-01-27
• Primary Completion: 2005-09
• Study Completion: 2009-06
• Status Verified: 2012-07
• Last Update Submitted: 2020-07-30
• Last Update Posted: 2020-08-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Optimal dose	7 months

Secondary Outcome Measures

Name	Time	Method
Immunological response (peptide-specific T cell generation, skin test immunohistology)	7 months
Clinical response (disease improvement or disease progression)	7 months
Safety of administering MART-1 adenovirus transduced dendritic cells	7 months

Trial Locations

Locations (1)

Jonsson Comprehensive Cancer Center at UCLA; 🇺🇸 Los Angeles, California, United States